{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:24:23Z","timestamp":1785536663455,"version":"3.56.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"46","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BBS\/E\/I\/00001792"],"award-info":[{"award-number":["BBS\/E\/I\/00001792"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spanish Ministry of Science, Innovation and Universities","award":["AGL2017-82570-R"],"award-info":[{"award-number":["AGL2017-82570-R"]}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council\/Pirbright Institute Fellowship Programme","doi-asserted-by":"publisher","award":["BBS\/E\/I\/00002536"],"award-info":[{"award-number":["BBS\/E\/I\/00002536"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.vaccine.2018.09.065","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T13:41:26Z","timestamp":1539006086000},"page":"7003-7010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model"],"prefix":"10.1016","volume":"36","author":[{"given":"Mine","family":"Aksular","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Calvo-Pinilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Mar\u00edn-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ortego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam C.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda A.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3453-8557","authenticated-orcid":false,"given":"Javier","family":"Castillo-Olivares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.09.065_b0005","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0147-9571(94)90046-9","article-title":"African horse sickness virus structure","volume":"17","author":"Roy","year":"1994","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.065_b0010","doi-asserted-by":"crossref","first-page":"7858","DOI":"10.1128\/JVI.00517-12","article-title":"Structural insight into African horsesickness virus infection","volume":"86","author":"Manole","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.09.065_b0015","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1006\/viro.1993.1537","article-title":"Neutralizing epitopes of African horsesickness virus serotype 4 are located on VP2","volume":"196","author":"Burrage","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.09.065_b0020","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1099\/0022-1317-81-4-993","article-title":"Identification of antigenic regions on VP2 of African horsesickness virus serotype 3 by using phage-displayed epitope libraries","volume":"81","author":"Bentley","year":"2000","journal-title":"J General Virol"},{"key":"10.1016\/j.vaccine.2018.09.065_b0025","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1006\/viro.1999.9680","article-title":"Antigenic profile of African horse sickness virus serotype 4 VP5 and identification of a neutralizing epitope shared with bluetongue virus and epizootic hemorrhagic disease virus","volume":"257","author":"Martinez-Torrecuadrada","year":"1999","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.09.065_b0030","unstructured":"Coetzer JAW, Guthrie AJ. African horse sickness In: Coetzer JAW, Tustin RC, editors. Infectious Diseases of Livestock. 2nd ed. Cape Town Southern Africa: Oxford University Press; 2004. p. 1231\u201346."},{"key":"10.1016\/j.vaccine.2018.09.065_b0035","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1051\/vetres:2004021","article-title":"African horse sickness","volume":"35","author":"Mellor","year":"2004","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2018.09.065_b0040","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1016\/j.vaccine.2008.07.037","article-title":"Evaluation of the pathogenicity of African Horsesickness (AHS) isolates in vaccinated animals","volume":"26","author":"von Teichman","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.065_b0045","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.3201\/eid2212.160718","article-title":"African horse sickness caused by genome reassortment and reversion to virulence of live, attenuated vaccine viruses, South Africa, 2004\u20132014","volume":"22","author":"Weyer","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.065_b0050","doi-asserted-by":"crossref","first-page":"8339","DOI":"10.1128\/JVI.00808-08","article-title":"Development of reverse genetics systems for bluetongue virus: recovery of infectious virus from synthetic RNA transcripts","volume":"82","author":"Boyce","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.09.065_b0055","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1016\/j.vaccine.2017.06.023","article-title":"Protective efficacy of multivalent replication-abortive vaccine strains in horses against African horse sickness virus challenge","volume":"35","author":"Lulla","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.065_b0060","doi-asserted-by":"crossref","first-page":"7405","DOI":"10.1128\/JVI.00548-16","article-title":"Assembly of replication-incompetent african horse sickness virus particles: rational design of vaccines for all serotypes","volume":"90","author":"Lulla","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.09.065_b0065","doi-asserted-by":"crossref","first-page":"8764","DOI":"10.1128\/JVI.01052-15","article-title":"VP2 exchange and NS3\/NS3a deletion in African Horse Sickness Virus (AHSV) in development of disabled infectious single animal vaccine candidates for AHSV","volume":"89","author":"van de Water","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.09.065_b0070","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01328-16","article-title":"Structural protein VP2 of African horse sickness virus is not essential for virus replication in vitro","volume":"91","author":"van Gennip","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.09.065_b0075","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12985-016-0574-7","article-title":"Requirements and comparative analysis of reverse genetics for bluetongue virus (BTV) and African horse sickness virus (AHSV)","volume":"13","author":"van Rijn PA, van de Water SG, Feenstra F, van Gennip RG","year":"2016","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2018.09.065_b0080","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.1016\/j.vaccine.2014.07.031","article-title":"Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus","volume":"32","author":"Kanai","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.065_b0085","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0264-410X(01)00445-5","article-title":"The protective efficacy of a recombinant VP2-based African horsesickness subunit vaccine candidate is determined by adjuvant","volume":"20","author":"Scanlen","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.065_b0090","first-page":"177","article-title":"New generation of African horse sickness virus vaccines based on structural and molecular studies of the virus particles","volume":"14","author":"Roy","year":"1998","journal-title":"Arch Virol Suppl"},{"key":"10.1016\/j.vaccine.2018.09.065_b0095","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2018.04.015","article-title":"The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host","volume":"154","author":"Calvo-Pinilla","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2018.09.065_b0100","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1016\/j.vaccine.2017.04.005","article-title":"Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination","volume":"35","author":"Manning","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.065_b0105","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1016\/j.vaccine.2014.04.036","article-title":"Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge","volume":"32","author":"Alberca","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.065_b0110","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.virusres.2013.12.002","article-title":"Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation","volume":"180","author":"Calvo-Pinilla","year":"2014","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2018.09.065_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016503","article-title":"A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR \u2013\/\u2013 mouse model","volume":"6","author":"Castillo-Olivares","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.09.065_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005997","article-title":"Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA)","volume":"4","author":"Chiam","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2018.09.065_b0125","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1016\/j.vaccine.2009.05.044","article-title":"Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus","volume":"27","author":"Guthrie","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.065_b0130","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1016\/j.vaccine.2010.06.105","article-title":"In vivo cross-protection to African horse sickness Serotypes 5 and 9 after vaccination with Serotypes 8 and 6","volume":"28","author":"von Teichman","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.065_b9000","series-title":"The Baculovirus Expression System: A Laboratory Guide","author":"King","year":"1992"},{"key":"10.1016\/j.vaccine.2018.09.065_b9005","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/bit.21177","article-title":"Quantitative real-time PCR for rapid and accurate titration of recombinant baculovirus particles","volume":"96","author":"Hitchman","year":"2007","journal-title":"Biotechnology and bioengineering."},{"key":"10.1016\/j.vaccine.2018.09.065_b0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2015.01.009","article-title":"Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge","volume":"116","author":"Calvo-Pinilla","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2018.09.065_b0140","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.vetimm.2012.01.016","article-title":"Virus-specific CD8(+) T-cells detected in PBMC from horses vaccinated against African horse sickness virus","volume":"146","author":"Pretorius","year":"2012","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2018.09.065_b0145","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.vetimm.2012.06.009","article-title":"An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses","volume":"149","author":"El Garch","year":"2012","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2018.09.065_b0150","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1016\/j.vaccine.2014.04.087","article-title":"Serological response of foals to polyvalent and monovalent live-attenuated African horse sickness virus vaccines","volume":"32","author":"Crafford","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.065_b0155","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.vetmic.2010.12.008","article-title":"One dose of a porcine circovirus 2 subunit vaccine induces humoral and cell-mediated immunity and protects against porcine circovirus-associated disease under field conditions","volume":"149","author":"Martelli","year":"2011","journal-title":"Vet Microbiol"},{"key":"10.1016\/j.vaccine.2018.09.065_b0160","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3389\/fimmu.2017.01649","article-title":"Single dose of consensus hemagglutinin-based virus-like particles vaccine protects chickens against divergent H5 subtype influenza viruses","volume":"8","author":"Wu","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2018.09.065_b0165","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4161\/hv.27567","article-title":"Single-dose monomeric HA subunit vaccine generates full protection from influenza challenge","volume":"10","author":"Mallajosyula","year":"2014","journal-title":"Human Vacc Immunother"},{"key":"10.1016\/j.vaccine.2018.09.065_b0170","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1016\/j.vaccine.2017.05.028","article-title":"A single dose of the novel chimeric subunit vaccine E2-CD154 confers early full protection against classical swine fever virus","volume":"35","author":"Suarez","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.09.065_b0175","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01190-17","article-title":"Single dose trivalent vesiculovax vaccine protects macaques from lethal ebolavirus and marburgvirus challenge","author":"Matassov","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.09.065_b0180","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1006\/viro.1994.1351","article-title":"Expression and characterization of the two outer capsid proteins of African horsesickness virus: the role of VP2 in virus neutralization","volume":"202","author":"Martinez-Torrecuadrada","year":"1994","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2018.09.065_b0185","first-page":"321","article-title":"Protein aggregation complicates the development of baculovirus-expressed African horsesickness virus serotype 5 VP2 subunit vaccines","volume":"65","author":"du Plessis","year":"1998","journal-title":"Onderstepoort J Vet Res"},{"issue":"Pt 9","key":"10.1016\/j.vaccine.2018.09.065_b0190","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1099\/0022-1317-77-9-2053","article-title":"Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge","volume":"77","author":"Roy","year":"1996","journal-title":"J General Virol"},{"key":"10.1016\/j.vaccine.2018.09.065_b0195","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s12033-010-9268-3","article-title":"Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines","volume":"45","author":"Krammer","year":"2010","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.vaccine.2018.09.065_b0200","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10529-013-1429-6","article-title":"Tnao38, high five and Sf9\u2013evaluation of host-virus interactions in three different insect cell lines: baculovirus production and recombinant protein expression","volume":"36","author":"Wilde","year":"2014","journal-title":"Biotechnol Lett"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18313410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18313410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T13:42:26Z","timestamp":1565271746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18313410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":42,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0264410X18313410"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.09.065","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.09.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}